Detail akcie Edwards Lifesci online

Business Summary: Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Edwards Lifesciences Corp revenues increased 12% to $6B. Net income decreased 8% to $1.4B. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 10% to $3.88B, Surgical Heart Valve Therapy segment increase of 12% to $999.3M, Transcatheter Mitral and Tricuspid Therapies segment increase of 70% to $197.6M, United States segment increase of 12% to $3.51B.